A state-transition model demonstrates that multicancer early detection blood tests significantly reduce late-stage cancer diagnoses and mortality, with annual screening intervals showing superior outcomes compared to biennial testing.
By:
Kerri Miller
Conexiant May 12, 2025
5
Key Takeaways
1
Annual blood-based multicancer early detection screening could reduce cancer mortality by 21% compared to usual care.
2
The study found annual screening led to 49% fewer late-stage diagnoses and 370 more cancer signals detected per 100,000 individuals.
3
Biennial screening showed benefits but ultimately prevented fewer deaths compared to annual screening.
4
The researchers used a state-transition model to evaluate the impact of different screening intervals on cancer outcomes.
5
MCED tests are designed to complement existing single-cancer screenings, not replace them.
Daily News
Stay up to date with the latest clinical headlines and other information tailored to your specialty.
Thank you for signing up for the Daily News alerts. You will begin receiving them shortly.
Bio:Kerri Miller is Editor at Conexiant, a medical content platform producing clinically-oriented articles, commentaries, and perspectives for healthcare professionals. In her role, she oversees editorial content across specialties including internal medicine, endocrinology, dermatology, family medicine, neurology, pediatrics, and more, ensuring evidence-based reporting and editing. ([conexiant.com](https://conexiant.com/author/kerri-miller/?utm_source=openai))
She contributes to Conexiant by writing or editing pieces on regulatory issues, clinical developments, and emerging healthcare trends. Recent examples include menopauses hormone therapy and FDA regulation of medical devices. ([conexiant.com](https://conexiant.com/obgyn/articles/rethinking-menopause-hormone-therapy/?utm_source=openai))
